EUGIA PHARMA Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EUGIA PHARMA, and what generic alternatives to EUGIA PHARMA drugs are available?
EUGIA PHARMA has one hundred and sixty-eight approved drugs.
There is one US patent protecting EUGIA PHARMA drugs. There are three tentative approvals on EUGIA PHARMA drugs.
There are ten patent family members on EUGIA PHARMA drugs in nine countries and three hundred and thirty-six supplementary protection certificates in eighteen countries.
Summary for EUGIA PHARMA
| International Patents: | 10 |
| US Patents: | 1 |
| Tradenames: | 142 |
| Ingredients: | 134 |
| NDAs: | 168 |
| Patent Litigation for EUGIA PHARMA: | See patent lawsuits for EUGIA PHARMA |
Drugs and US Patents for EUGIA PHARMA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eugia Pharma | KETAMINE HYDROCHLORIDE | ketamine hydrochloride | INJECTABLE;INJECTION | 076092-001 | Sep 30, 2008 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Eugia Pharma | IMATINIB MESYLATE | imatinib mesylate | TABLET;ORAL | 212773-002 | Jul 23, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Eugia Pharma | ESMOLOL HYDROCHLORIDE | esmolol hydrochloride | INJECTABLE;INJECTION | 205520-001 | Jul 23, 2015 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Eugia Pharma | MOXIFLOXACIN HYDROCHLORIDE | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 206242-001 | Oct 4, 2017 | AT1 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Eugia Pharma | LEVOFLOXACIN | levofloxacin | INJECTABLE;INJECTION | 202328-001 | Jan 24, 2013 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Eugia Pharma | CISATRACURIUM BESYLATE PRESERVATIVE FREE | cisatracurium besylate | INJECTABLE;INJECTION | 209665-001 | Oct 27, 2020 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Eugia Pharma Speclts | CYCLOPHOSPHAMIDE | cyclophosphamide | SOLUTION;INTRAVENOUS | 210735-001 | Aug 25, 2021 | RX | Yes | Yes | 9,662,342 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for EUGIA PHARMA Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2015256331 | ⤷ Try a Trial |
| Russian Federation | 2016147362 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2015171460 | ⤷ Try a Trial |
| China | 106456654 | ⤷ Try a Trial |
| South Korea | 20170008252 | ⤷ Try a Trial |
| Japan | 6516831 | ⤷ Try a Trial |
| European Patent Office | 3139929 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for EUGIA PHARMA Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1856135 | 2020/017 | Ireland | ⤷ Try a Trial | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTRATION NO/DATE: EU/1/19/1405 20200113 |
| 1115417 | 22/2006 | Austria | ⤷ Try a Trial | PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119 |
| 1499331 | SPC/GB13/034 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
| 2435024 | LUC00208 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), DE GLYCOPYRRONIUM (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE BUDESONIDE (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1468 20201210 |
| 0454436 | C970015 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927 |
| 1280520 | 92678 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725 |
| 1912999 | 1490062-5 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
